Phaseline

Companies › Impax Laboratories

Impax Laboratories: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 4; Neurology, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Carbidopa
DOPA decarboxylase inhibitor
DDCPhase 4Parkinson Disease; Anhedonia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06765668CarbidopaPhase 4Parkinson DiseaseNeurologyNov 2025
NCT06075771CarbidopaPhase 4AnhedoniaPsychiatryJan 2027
NCT06013956CarbidopaPhase 4Parkinson DiseaseNeurologyJun 2028

From the company's SEC filings

Complete response letters from FDA

Targets

DDC (1)

Companies with the same targets

PTC Therapeutics

Companies built like this

Sichuan Jishengtang Pharmaceutical Rapport Therapeutics Lipocine Intra-Cellular Therapies Upsher-Smith Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.